FindTrial
Sign In

Saxagliptin up-regulates nesfatin-1 secretion and inhibits erythrocyte aldose reductase activity in newly diagnosed type 2 diabetes

Saxagliptin up-regulates nesfatin-1 secretion and inhibits erythrocyte aldose reductase activity in newly diagnosed type 2 diabetes

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800015195
Enrollment
Unknown
Registered
2018-03-13
Start date
2015-02-28
Completion date
Unknown
Last updated
2018-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes

Interventions

treatment:Saxagliptin
Control group:acarbose

Sponsors

Jiangsu Jiankang Vocational College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 69 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria for the study were HbA1c levels 7.0%~8.5%.

Exclusion criteria

Exclusion criteria: allergy or hypersensitivity to any of the drugs components, hypertension, hyperlipidemia, established cardiovascular disease (patients at least 40 years of age and had a history of a clinical event associated with atherosclerosis involving the coronary, cerebrovascular or peripheral vascular system), heart failure NYHA class III and IV, abnormal function of the kidney or liver, malignant disease, active infectious disease, pregnancy, or breastfeeding

Design outcomes

Primary

MeasureTime frame
nesfatin-1;—

Countries

China

Contacts

Public ContactCHEN Kuan-lin

JIANGSU JIANKANG VOCATIONAL COLLEGE

53972178@qq.com+86 13376071599

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026